NEW YORK (360Dx) – I-Med Pharma announced this week it has won a patent case in Canada against TearLab related to the I-Pen Osmolarity System.

In February 2016, TearLab filed suit in the Federal Court of Canada alleging that I-Med Pharma's I-Pen infringed on the Canadian patent for the TearLab Osmolarity System. TearLab sought a permanent injunction to keep the I-Pen off the market, as well as damages, according to I-Med Pharma.

This week, the court invalidated TearLab's patent claims and awarded costs to I-Med Pharma. TearLab said it plans to appeal the ruling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.